Testing Spread and Implementation of Novel Methicillin Resistant Staphylococcal Aureus (MRSA)-Reducing Practices

Sponsor

MaineHealth (Other)

Overall Status

Completed

CT.gov ID

NCT01255943

Collaborator

Agency for Healthcare Research and Quality (AHRQ) (U.S. Fed), Indiana University School of Medicine (Other)

175

Enrollment

Location

Duration (Months)

8.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to implement strategies for improved efficiency and waste reduction ("Toyota Lean") and positive deviance, a social behavioral change process, utilizing frontline healthcare personnel to reduce infection bloodstream infection and MRSA infection in outpatient dialysis care. In two outpatient dialysis units, dialysis unit healthcare staff will be educated in Toyota lean techniques and conduct periodic "discovery and action" dialogues to identify and implement care process changes to reduce infection. Outcomes to be monitored will include incidence of bloodstream infections and MRSA infections of all types. Data will be assessed at quarterly intervals using interrupted time series analysis.

Condition or Disease	Intervention/Treatment	Phase
Blood Stream Infections MRSA Infections	Behavioral: healthcare staff processes for infection prevention

Study Design

Study Type:

Observational

Actual Enrollment :

175 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Testing Spread and Implementation of Novel MRSA-Reducing Practices

Study Start Date :

Jul 1, 2010

Actual Primary Completion Date :

Apr 1, 2012

Actual Study Completion Date :

Apr 1, 2012

Arms and Interventions

Arm	Intervention/Treatment
prevalent hemodialysis patients These patients are observed in two outpatient dialysis units with a combined census of approximately 175 patients	Behavioral: healthcare staff processes for infection prevention Toyota lean and positive deviance discovery and action dialogues to facilitate process improvement

Arm

Intervention/Treatment

prevalent hemodialysis patients

These patients are observed in two outpatient dialysis units with a combined census of approximately 175 patients

Behavioral: healthcare staff processes for infection prevention

Toyota lean and positive deviance discovery and action dialogues to facilitate process improvement

Outcome Measures

Primary Outcome Measures

Incidence of bloodstream infections [14 months]

Secondary Outcome Measures

Incidence of MRSA infections [14 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria: all hemodialysis patients at two outpatient dialysis units

Exclusion Criteria:peritoneal dialysis patients

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Maine Medical Center	Portland	Maine	United States	04102

Sponsors and Collaborators

MaineHealth
Agency for Healthcare Research and Quality (AHRQ)
Indiana University School of Medicine

Investigators

Principal Investigator: Mark G Parker, MD, MaineHealth

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Mark Parker, Director, Division of Nephrology and Transplantation, MaineHealth

ClinicalTrials.gov Identifier:

NCT01255943

Other Study ID Numbers:

HHSA290200600013

First Posted:

Dec 8, 2010

Last Update Posted:

Nov 9, 2021

Last Verified:

Nov 1, 2021

Keywords provided by Mark Parker, Director, Division of Nephrology and Transplantation, MaineHealth

MRSA

bloodstream infections

hemodialysis

Additional relevant MeSH terms:

Infections

Communicable Diseases

Sepsis

Study Results

No Results Posted as of Nov 9, 2021